News Quantified

CUE – cue biopharma, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Cue Biopharma Announces CEO Transition [Yahoo! Finance]

Cue Biopharma Announces CEO Transition [TheStreet.com]

Cue Biopharma Announces CEO Transition

Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026 [Yahoo! Finance]

Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026

Form DEFA14A Cue Biopharma, Inc.

Form 8-K Cue Biopharma, Inc. For: Mar 23

Form S-3 Cue Biopharma, Inc.

Form ARS Cue Biopharma, Inc. For: Dec 31

Form 8-K Cue Biopharma, Inc. For: Mar 16

Top News Gainers

3/19 Cue Biopharma Inc (NASDAQ: CUE) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 24.3%

2/19 Cue Biopharma’s Therapeutic Immuno-STAT Platform to be Featured in Merck Presentation at Antigen-Specific Immune Tolerance Drug Development Summit 14.5%

4/20 Cue Biopharma Announces Clinical Trial Collaboration Agreement with Merck to Evaluate CUE-101 in Combination with KEYTRUDA® (pembrolizumab) as First-line Treatment For HPV+ Recurrent/Metastatic Head and Neck Cancer 13.9%

6/7 Form 4 Cue Biopharma, Inc. For: Jun 06 Filed by: PASSERI DANIEL R 13.8%

4/8 Cue Biopharma Inc (NASDAQ: CUE) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating on the stock. 9.0%

7/25 Cue Biopharma Inc (NASDAQ: CUE) is now covered by analysts at Robert W. Baird. They set an "outperform" rating on the stock. 8.2%

4/28 Cue Biopharma Inc (NASDAQ: CUE) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 7.8%

1/7 Does Market Volatility Impact Cue Biopharma, Inc.'s (NASDAQ:CUE) Share Price? [Yahoo! Finance News] 7.7%

12/21 Hedge Funds Have Never Been This Bullish On Cue Biopharma, Inc. (CUE) [Yahoo! Finance News] 6.2%

10/2 Cue Biopharma to Present Corporate Overview and Update on Clinical Development Progress for CUE-101 at the Cantor 2019 Global Healthcare Conference 6.2%

Top News Decliners

3/12 Form 10-K Cue Biopharma, Inc. For: Dec 31 -20.4%

3/17 Cue Biopharma Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights -13.7%

12/27 Form 4 Cue Biopharma, Inc. For: Dec 23 Filed by: MARLETT CHRISTOPHER A -8.9%

3/11 Cue Biopharma Inc (NASDAQ: CUE) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -8.0%

3/6 Cue Biopharma Inc (NASDAQ: CUE) had its price target raised by analysts at JMP Securities from $22.00 to $30.00. They now have an "outperform" rating on the stock. -7.9%

3/26 Form 4 Cue Biopharma, Inc. For: Mar 24 Filed by: Pienta Kenneth -7.1%

2/14 Form SC 13G Cue Biopharma, Inc. Filed by: Avoro Capital Advisors LLC -6.5%

7/9 Form 10-Q/A Cue Biopharma, Inc. For: Mar 31 -6.2%

6/5 Form 8-K Cue Biopharma, Inc. For: Jun 05 -6.0%

9/18 Cue Biopharma Inc (NASDAQ: CUE) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -5.2%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day